- Home
- VFS vs EXEL Comparison
VFS vs EXEL Comparison
Compare VFS & EXEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VFS
- EXEL
- Stock Information
- Founded
- VFS 2017
- EXEL 1994
- Country
- VFS Vietnam
- EXEL United States
- Employees
- VFS N/A
- EXEL N/A
- Industry
- VFS Blank Checks
- EXEL Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- VFS Finance
- EXEL Health Care
- Exchange
- VFS Nasdaq
- EXEL Nasdaq
- Market Cap
- VFS 9.0B
- EXEL 9.4B
- IPO Year
- VFS N/A
- EXEL 2000
- Fundamental
- Price
- VFS $3.05
- EXEL $36.93
- Analyst Decision
- VFS Strong Buy
- EXEL Buy
- Analyst Count
- VFS 3
- EXEL 18
- Target Price
- VFS $8.00
- EXEL $37.24
- AVG Volume (30 Days)
- VFS 569.2K
- EXEL 2.9M
- Earning Date
- VFS 04-16-2025
- EXEL 04-29-2025
- Dividend Yield
- VFS N/A
- EXEL N/A
- EPS Growth
- VFS N/A
- EXEL 170.77
- EPS
- VFS N/A
- EXEL 1.76
- Revenue
- VFS $1,517,342,313.00
- EXEL $2,168,701,000.00
- Revenue This Year
- VFS N/A
- EXEL $5.45
- Revenue Next Year
- VFS $57.08
- EXEL $10.32
- P/E Ratio
- VFS N/A
- EXEL $20.99
- Revenue Growth
- VFS 64.54
- EXEL 18.49
- 52 Week Low
- VFS $2.26
- EXEL $20.14
- 52 Week High
- VFS $6.42
- EXEL $40.02
- Technical
- Relative Strength Index (RSI)
- VFS 27.24
- EXEL 52.55
- Support Level
- VFS $3.20
- EXEL $37.26
- Resistance Level
- VFS $3.45
- EXEL $40.02
- Average True Range (ATR)
- VFS 0.17
- EXEL 1.16
- MACD
- VFS -0.04
- EXEL 0.05
- Stochastic Oscillator
- VFS 9.78
- EXEL 44.02
About VFS VinFast Auto Ltd.
VinFast Auto Ltd manufactures cars, and motor vehicles, renders leasing activities, trades smartphones, and related businesses. The company is engaged in designing and manufacturing premium EVs, e-scooters, and e-buses. The company's initial EV product line is an all-new range of fully electric A- through E-segment SUVs. The Company has three reportable segments, namely Automobiles, E-scooter, Spare parts & Aftermarket services. The Automobiles segment includes the design, development, manufacturing, and sales of cars and electric buses; The E-scooter segment includes the design, development, manufacturing, and sales of e-scooters; the Spare parts & Aftermarket services segment includes the sales of spare parts and rendering of aftermarket services for automobiles and e-scooters.
About EXEL Exelixis Inc.
Exelixis is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its lead molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.